lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's billions then trillions. Sorry you can't keep up. Science is hard.
NYSE allows immediate uplist for companies previously listed on another exchange.
Once we get above $4 we can have an instant uplist to NYSE which I suspect Linda Powers will do as soon as it's possible. The question really happens to be which firm will be our DMM? Not GTS or Citadel ;)
Billion and billions in market cap headed our way.
Trillion dollar technology!
Time to pop a bottle!
Congratulations Linda Powers and the entire Northwest Biotherapeutics team!
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://www.researchsquare.com/article/rs-2591941/v1
https://nwbio.com/glioblastoma-drug-development-summit/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671
HappyLibrarian, Jerry Campbell, and other moderators.
Will you please pin the revelatory GBM presentation Marnix Bosch gave on 3/15/2023?
https://nwbio.com/glioblastoma-drug-development-summit/
At this event Northwest Biotherapeutics' CTO reiterated that DCVax may be the platform for treating all solid tumors. We also learned that rGBM patients can have additional resections upon tumor reoccurrence from which subsequent batches of vaccine are made prolonging patient survival even further than the Landmark PIII Trial. I hope you will consider helping make all readers on this forum aware of these extremely significant updates!
Thank you,
COl
Optune has horrible survival data. JP Morgan doesn't like Novocure.
Glioblastoma mutates so the neoantigens present on it are not the same after recurrence. So they made a new batch of DCVax after subsequent resection. I wouldn't call it a booster since the composition of the vaccine isn't same as the first tranche of doses. They made the vaccine from the mutated recurrent tumor.
From the compassionate use we know now that rGBM patients can live even longer than in the Landmark PIII trial if they have another set of vaccine made from the further mutated recurrent tumor. That's pretty profound as it expands survival significantly thus the cost benefit analysis (QALY) used for insurance reimbursement. There's really nothing stopping DCVax approval.
Following the "Bright Line Test," in fact preliminary negotiations, as a matter of law, are never material until an agreement has been reached upon in terms of price and structure. Being offered $20 billion isn't an agreement between both parties. It's an informal offer. It doesn't need to be disclosed to shareholders.
Yeah, like Toucan did with Flaskworks. You are batting 1000 on your predictions.
Oncovir are a small private company. It's hard to know without seeing their books. They should be worth no more than $100M though probably not above $10M. Equity partner could help facilitate that deal easily after DCVax approval. We could also do the same, once our stock gets high enough, as with Flaskworks. The synergy with PolyICLC and DCVax are evident in the UCLA combination trial data.
PolyICLC inhibits meyloid cells, that interfere with the immune response, allowing the T cells activated by DCVax to more effectively destroy the tumor. We definitely should own Oncovir in my opinion or at a minimum have an exclusive licensing deal that makes us their sole partner. I would rather we own the technology outright as this eliminates counterparty risk while allowing us to determine the development of PolyICLC.
Bringing an initial offer, at the beginning of discussions, to the board isn't the same as announcing it to shareholders because the SEC requires disclosure. They do not. The Twitter negotiations were voluntarily made public because of ego not due to SEC rules. You fail to understand these distinctions.
Will Northwest Biotherapeutics buy Oncovir? I can see that helping us uplist post regulatory approval. A few equity partners could help facilitate that deal which makes a lot more sense than buying Advent given the immense synergy that exits between DCVax and PolyICLC.
Why did Seagen disclose their talks with Merck when the SEC does not mandate that disclosure? Because they wanted to be bought! They also believed their pipline was understood enough to command a price worthy of its intrinsic value. Putting that out allowed them to attract attention of rivals like Pfizer. They had leverage to then turn down Merck.
I would rather Northwest Biotherapeutics engage in such manipulation when we have a few approvals under our belt and a much higher stock price. Now isn't the time for us to engage in buyout talks when we can get a much higher price after regulators unequivocally endorse DCVax as well as our novel manufacturing approach. So let management deliver that outcome then we can see the state of play.
Wrong the SEC doesn't require buyout negotiations to be disclosed to investors until a final deal has been agreed to by both parties. They must be presented to shareholders when a deal has been structured by both management teams but not until that conclusion has been reached. This explains why we don't know the exact details of the failed attempt Merck made to buy Seagen. We know talks occurred because management teams chose to disclose that reality not because SEC rules required that disclosure.
The fact that we don't have a formal deal to me signifies that Linda Powers wants to maximize shareholder value. I wouldn't want her to disclose low ball bids anyway especially when we have matters before regulators. Why would she want to advertise DCVax is only worth a hypothetical 10 billion, the price of a possible failed ask, when we know it's worth a lot more?
It's clear approvals are the goal not selling for pennies on the dollar. Given we own trillion dollar technology it's better we wait for that to be proven out then we will realize maximal gains. If you can't wait then that's your prerogative. Management are focused on delivering the product not short term pumping of their stock or a cheap sale. It can be frustrating to not know the inside story but that's the reality for us as shareholders. I trust them to deliver results as they have at every juncture.
NVCRs declining sales and shoddy trial data provide the justification for the downgrade. The marketplace does not value TTF technology. The subtext of a new entrant to the market isn't stated but I suspect it's well known given our JAMA article was the most read ever in the history of that world-class publication.
Of course they know about DCVax. They're not going to cover us until we're off OTC. I didn't think about the Mafia boiler room stigma. Thanks to biosectinvestor for making that barrier to coverage more clear. I thought family offices could carry us by now but it seems we have to wait a little longer.
Well said
Yeah, nobody wants to own trillion dollar technology for 15 billion.
Trillion dollar technology.
As Novocure gets downgraded by JP Morgan we must ask why? DCVax, obviously, since it can possibly act as a long-term cancer vaccine showing benefit with dosing regimens that extend beyond what we saw in the PIII trial. Instead of wearing the Brain Microwave for life, imagine a 60 year old GBM patient getting a monthly or quarterly maintenance dose of DCVax for the next 30 years!
Trillion-dollar company once that's applied to all solid tumors!
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://www.researchsquare.com/article/rs-2591941/v1
https://nwbio.com/glioblastoma-drug-development-summit/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671
The compassionate use results should be highlighted on Bloomberg Terminal. If the firm can't speak about trial data with matters before regulators well this shouldn't be a big deal as it's outside the trial. We need some good news and it's time the PR efforts get more aggressive. This is the platform for all solid tumors. Time we begin to tell the world and stop letting the scientists speak for management. The firm needs to stand up and get the news out. While I love seeing Ken Griffin lose money to us in court that isn't going to bring us hundreds of billions in revenue like DCVax. I ask everyone on here email management and demand these compassionate use results be highlighted in a PR. These profound results are clearly material data which the entire market should be told about immediately.
Dave Innes should PR this presentation with more information about the compassionate use case results. This is clearly material data which an investor would find worthy of making a trade.
Survival numbers for agnostic platform makes me woozy in the head.
100B market cap by Q4 2024
Keytruda does 20B revenue a year so the global potential immunotherapy market certainly isn't worth 100B. It's many trillions. If DCVax can capture large portion of that market then Linda Powers will be as big if not bigger than Bill Gates in terms of positive impact on humanity.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://www.researchsquare.com/article/rs-2591941/v1
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671
Wrong, but DCVax is the answer for all brain tumors.
The MHRA MIA has nothing to do with meeting patient demand in the EU. The loan was to meet that demand but that isn't in anyway tied to the MIA.
Landmark Trial Results!
MHRA Trial Endorsement (PIP)!
Innovative Manufacturing!
JAMA!
Global Patent Protection!
My 400K shares should be worth $30M once Northwest Biotherapeutics obtains global approval on nGBM and rGBM indications.
That may take time but I see no reason to sell these shares since I can borrow against them once NWBO are off OTC. I also didn't get over my skis when making investment decisions.
In my personal opinion as a retail investor representing myself alone, and not providing investment advice, the false panic created on this forum daily simply does not reflect the deep value present in Northwest Biotherapeutics stock!
Billionaire Robert Hefner agrees:
Our Northwest Biotherapeutics (NWBO) investee “partner” likely has just made one of the biggest breakthroughs in the history of cancer. We know that is a really big statement so why do we at GHK believe that is possible? Because we believe the doors through which major cancer breakthroughs must pass are the human immune system, immunotherapies and personalized vaccines and NWBO has just leaped through those doors with its personalized DCVax vaccine made from your own cells.
You can argue about trial statistics until the cows come home but the bottom line is 1) people living longer 2) quality of life during treatments and 3) the cost of treatments.
During NWBO’s 16-year Phase III trial to treat glioblastoma (GBM), one of the most difficult and lethal of all solid tumor cancers 1) more people lived longer, 2) it is safe with virtually no side effects occurring and 3) NWBO estimates treatments will cost about half as much as Standard of Care chemotherapy and radiation treatments. So for the first time ever, GBM patients can have hope! And can hope like prayer increase the effectiveness and energy of the immune system? We think so.
We are aware we stuck our necks out when we said “possibly one of the biggest breakthroughs in the history of cancer”. So we have listed below our three principle reasons so you can decide for yourself:
After 417 failed GBM trials treating 31,952 patents over decades, DCVax-L is first treatment that gives GBM patients a meaningful chance to live longer, some now living 9 to as many as 19 years and counting.
DCVax was conceived and created not for glioblastoma alone but as a personalized tool of your own immune system to defeat all solid tumor cancers and that’s 90% of all cancers.
Since DCVax’s creation NWBO has amassed an enormous rich databank containing masses of information on patients, treatments, and DCVax’s use against 15 different solid tumor cancers that has not yet been analyzed by artificial intelligence (AI). We believe that in the near future when these vast amounts of data and information are teamed with AI and some of the world’s leading scientists and doctors that future generations of DCVax vaccines and protocols will experience great leaps forward in effectiveness at lower and lower costs for 90% of all cancers.
So to sum up, we believe NWBO with its DCVax immunotherapy personalized vaccines has leaped through the doors and will play a vital role in humanities great drive to defeat cancer once and for all.
Dr. Ashkan is the genius behind this viral vid of him performing brain surgery while his patient was awakened to play the violin…mid-surgery. He told me he champions DCVax-L bc of trial data along with what he’s seen first-hand from his patients. $NWBOhttps://t.co/XFTeSPFtH5
— Wade Kovash (@wkovash) June 6, 2022
Watch one of the world’s preeminent neurosurgeons explain the significance of $NWBO ‘s Phase III trial of DCVax-L. The results are groundbreaking and represent an enormous advancement in one of the most tragic cancers. https://t.co/eQw5tAsivK
— Wade Kovash (@wkovash) June 6, 2022
Hold on to your shares! We are the future of oncology!
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://www.researchsquare.com/article/rs-2591941/v1
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671
So you're saying the National Academy of Sciences are liars when they state regarding Linda Powers:
She was co-lead negotiator for the U.S. on the North American Free Trade Agreement, financial sector agreement, which opened banking, securities, insurance, pension fund and related opportunities in Canada and Mexico.
During the 1980s, Ms. Powers practiced law, specializing in corporate mergers, acquisitions and financings, and certain kinds of intellectual property transactions. While working for the headquarters of the European Union in Brussels, she was responsible for drafting the initial intellectual property rules that now govern know-how licensing in the European Union.
I agree 100%. Management are moving ahead while the incumbents are left in the dust.
It's well known that IDH mutated astrocytomas lead to a better prognosis. DCVax does very well against those tumors. I don't really see competition given we already have PIII trial results published in JAMA as well as global manufacturing capacity.
IDH-mut isn't Glioblastoma though DCVax does very well against this type of brain tumor an Astrocytoma.
Michael Bigger, Steve Derby, Robert Hefner, John Fife, and 44,996 other NWBO shareholders disagree with your conclusions.
Bona-fide bovine excrement devoid of any substance except logical fallacies.
Shorts will be collecting unemployment. Enjoy living in Hoovertown.
Shorts are going to be insolvent.
The company cannot issue precise guidance because it's not possible to provide accurate timelines on regulatory approval. Those who want that are being disingenuous. MHRA inspected Sawston last month. We are due for good news.